<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00261378</url>
  </required_header>
  <id_info>
    <org_study_id>CA1008</org_study_id>
    <nct_id>NCT00261378</nct_id>
  </id_info>
  <brief_title>Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation</brief_title>
  <acronym>PRECISIONV</acronym>
  <official_title>Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation (PRECISION V)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocompatibles UK Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocompatibles UK Ltd</source>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and efficacy of DC Bead™ delivered by
      intra-arterial embolisation for the treatment of Hepatocellular Carcinoma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate measured according to RECIST and EASL</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alpha Fetal Protein (AFP) over time</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospital discharge</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other procedures or interventions required</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiotoxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Tumour Response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care resource use</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient quality of life</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Progression</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">212</enrollment>
  <condition>Primary Liver Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transarterialchemoembolisation (TACE)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DC Bead with Doxorubicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Patients with a confirmed diagnosis of HCC according to the EASL criteria for
             diagnosis, see appendix 4 and staged according to the BCLC criteria.

          -  Patient chooses to participate and has signed the informed consent document

          -  Age above 18 years old

          -  Patients with HCC not suitable for resection or percutaneous ablation according to the
             BCLC Staging classification, see Figure 2.

          -  Patient is eligible for resection or percutaneous ablation but the treatment is
             unfeasible or the patient has declined. This decision must be documented in the
             patient's records.

          -  Patient is eligible for chemoembolisation prior to transplantation and the expected
             transplant waiting time exceeds 6 months.

          -  Patients who demonstrates recurrence following potentially curative treatment
             (resection and percutaneous ablation) who have clearly measurable disease according to
             RECIST or EASL

          -  Patients with Performance Status ECOG 0 and 1

          -  Patients with well preserved liver function (Child-Pugh A and B)

          -  Patients with bilobar disease who can be treated superselectively in a single session
             or both lobes able to be treated within 3 weeks.

        Exclusion criteria

          -  Patients with another primary tumour, with the exception of conventional basal cell
             carcinoma or superficial bladder neoplasia

          -  Patients previously treated with transarterial embolisation (with or without
             chemotherapy).

          -  Patients previously treated with anthracyclines (ie doxorubicin).

          -  Patients' whose only measurable disease is within an area of the liver previously
             subjected to radiotherapy.

          -  Advanced liver disease:

               -  Child-Pugh C,

               -  active gastrointestinal bleeding,

               -  encephalopathy or clinically relevant ascites.

          -  Bilirubin levels &gt;3mg/dl

          -  Advanced tumoural disease:

               -  BCLC class C, (vascular invasion including segmental portal obstruction,
                  extrahepatic spread or cancer-related symptoms= ECOG 2, 3 and 4) or

               -  BCLC class D (WHO performance status 3 or 4, Okuda III stage) or

               -  Diffuse HCC defined as &gt;50% tumour involvement of the whole liver

          -  Any contraindication for doxorubicin administration:

               -  serum bilirubin &gt;5mg/dL,

               -  WBC &lt;3000 cells/mm3

               -  neutrophil &lt;1500 cells/mm3,

               -  cardiac ejection fraction &lt;50 percent assessed by isotopic ventriculography,
                  echocardiography or MRI

          -  Any contraindication for hepatic embolisation procedures:

               -  porto-systemic shunt,

               -  hepatofugal blood flow;

               -  impaired clotting tests (platelet count &lt;50000/mm3, prothrombin activity &lt;50
                  percent),

               -  renal insufficiency/failure, serum creatinine &gt; 2mg/dl (177umol/l)

               -  severe atheromatosis,

               -  AST and/or ALT &gt;5x ULN or, when greater &gt;250U/l

          -  Women who are pregnant or breast feeding

          -  Allergy to contrast media

          -  Contraindication to hepatic artery catheterisation, such as severe peripheral vascular
             disease precluding catheterisation

          -  The availability of alternative therapies those, in the judgment of the physician
             (referring or treating), are more appropriate for the patient

          -  Any co-morbid disease or condition or event that, in the investigator's judgment,
             would place the patient at undue risk, that would preclude the safe use of DC Bead™,
             or TACE

          -  Patients who are contraindicated for MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Johannes Lammer</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Allgemines Krankenhaus, Vienna, 1090, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemines Krankenhaus Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L'Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Archet II</name>
      <address>
        <city>Nice</city>
        <zip>6200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann-Wolfgang-Goethe-Universitat</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes Guttenberg</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultat fur Klinische Medizin Mannheim Universitat</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve</name>
      <address>
        <city>Geneve</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsspital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2005</study_first_submitted>
  <study_first_submitted_qc>December 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2005</study_first_posted>
  <last_update_submitted>June 14, 2010</last_update_submitted>
  <last_update_submitted_qc>June 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Clinical Research Director</name_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma (HCC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

